Effective targeting of primitive AML CD34+ cells by the second‐generation proteasome inhibitor carfilzomib

E-ISSN： 1365-2141|171|4|652-655

ISSN： 0007-1048

Source： BRITISH JOURNAL OF HAEMATOLOGY, Vol.171, Iss.4, 2015-11, pp. : 652-655

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

CD34-Negative Stem Cells

Transfusion Medicine and Hemotherapy, Vol. 26, Iss. 2, 2004-11 ,pp. : 2-5

Karger

Access to resources Recommend Favorite

Effects of the proteasome inhibitor, bortezomib, on cytodifferentiation and mineralization of periodontal ligament cells

JOURNAL OF PERIODONTAL RESEARCH, Vol. 50, Iss. 2, 2015-04 ,pp. : 248-255

John Wiley & Sons Inc

Access to resources Recommend Favorite

CD34+ and CD133+ Primitive Stem Cell Expression in Peripheral Blood: Considering Gender, Age, and Smoking

Transfusion Medicine and Hemotherapy, Vol. 36, Iss. 2, 2009-03 ,pp. : 129-134

Karger

Access to resources Recommend Favorite

Second‐generation autofluorescence imaging for colorectal neoplasia

DIGESTIVE ENDOSCOPY, Vol. 27, Iss. S1, 2015-04 ,pp. : 46-46

John Wiley & Sons Inc

Access to resources Recommend Favorite

Drug resistance and BCR‐ABL kinase domain mutations in Philadelphia chromosome–positive acute lymphoblastic leukemia from the imatinib to the second‐generation tyrosine kinase inhibitor era: The main changes are in the type of mutations, but not in the frequency of mutation involvement

CANCER, Vol. 120, Iss. 7, 2014-04 ,pp. : 1002-1009

John Wiley & Sons Inc

Access to resources Recommend Favorite